Migraine as a process - Challenges in the effective management of migraine

Functional Neurology

Volumn 23, Issue 3, 2008, Pages 153-160

  Ferrari, Michel D ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; BOTULINUM TOXIN A; BUTALBITAL; CALCITONIN GENE RELATED PEPTIDE; CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONIST; ISOMETHEPTENE; NAPROXEN; NARATRIPTAN; NONSTEROID ANTIINFLAMMATORY AGENT; OREXIN A; OREXIN B; PARACETAMOL; PLACEBO; PROPRANOLOL; RIZATRIPTAN; ROFECOXIB; SUMATRIPTAN; TOLFENAMIC ACID; TOPIRAMATE; TRIMEBUTINE; ZOLMITRIPTAN;

ALLODYNIA; CLINICAL FEATURE; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; DRUG TREATMENT FAILURE; GENE MUTATION; HEADACHE; HEMIPLEGIC MIGRAINE; HUMAN; MEDICAL ERROR; MEDICAL RESEARCH; MIGRAINE; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PROGNOSIS; PROTEIN FUNCTION; RECURRENT DISEASE; REMISSION; RISK FACTOR;

DISEASE MANAGEMENT; HUMANS; MIGRAINE DISORDERS; PROGNOSIS; RISK FACTORS;

EID: 58649107082     PISSN: 03935264     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (19)

1. Cady R, Martin V, Mauskop A et al. Symptoms of cutaneous sensitivity pre-treatment and post-treatment: results from the rizatriptan TAME studies. Cephalalgia 2007;27: 1055-1060
2. Obermann M, Yoon MS, Dommes P et al. Prevalence of trigeminal autonomic symptoms in migraine: a population-based study. Cephalalgia 2007;27:504-509
3. Ho TW, Mannix LK, Fan X et al. Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. MK-0974 Protocol 004 study group. Neurology 2008;70:1304-1312
4. Ferrari MD, Roon KI, Lipton RB, Goadsby PJ. Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 2001;358:1668-1675
5. Scher AI, Stewart WF, Ricci JA, Lipton RB. Factors associated with the onset and remission of chronic daily headache in a population-based study. Pain 2003;106:81-89
6. Bigal ME, Lipton RB. Modifiable risk factors for migraine progression. Headache 2006;46:1334-1343
7. Kruit MC, van Buchem MA, Hofman PA et al. Migraine as a risk factor for subclinical brain lesions. JAMA 2004;291: 427- 434
8. Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache 2001;41: 646-657
9. Diener H-C, Bussone G, Van Oene JC, Lahaye M, Schwalen S, Goadsby PJ. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia 2007;12:814-823
10. Silberstein SD, Lipton RB, Dodick DW et al. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial. Headache 2007;47:170-180
11. Silvestrini M, Bartolini M, Coccia M, Baruffaldi R, Taffi R, Provinciali L. Topiramate in the treatment of chronic migraine. Cephalalgia 2003;23:820-824
12. Wilkinson SM, Becker WJ, Heine JA. Opiate use to control bowel motility may induce chronic daily headache in patients with migraine. Headache 2001;41:303-309
13. Isler H. Migraine treatment as a cause of chronic migraine. In: Rose FC ed Advances in Migraine Research and Therapy. New York NY; Raven Press 1982:159-164
14. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter: the utility of neuroimaging in the evaluation of headache in patients with normal neurologic examinations (summary statement). Neurology 1994;44:1353-1354
15. Wang HZ, Simonson TM, Greco WR, Yuh WT. Brain MR imaging in the evaluation of chronic headache in patients without other neurologic symptoms. Acad Radiol 2001;8: 405-408
16. Pascual J, Fité B, López-Gil A. Comparison of triptan tablet consumption per attack: a prospective study of mi-graineurs in spain. Headache 2002;42:93-98
17. Bell CF, Foley KA, Barlas S, Solomon G, Hu XH. Time to pain freedom and onset of pain relief with rizatriptan 10 mg and prescription usual-care oral medications in the acute treatment of migraine headaches: A multicenter, prospective, open-label, two-attack, crossover study. Clin Ther 2006;28: 872-880
18. Krymchantowski AV, Bigal ME. Rizatriptan versus rizatriptan plus rofecoxib versus rizatriptan plus tolfenamic acid in the acute treatment of migraine. BMC Neurol 2004;4:10
19. Krymchantowski AV, Filho PF, Bigal ME. Rizatriptan vs rizatriptan plus trimebutine for the acute treatment of migraine: a double-blind, randomized, cross-over, placebo-controlled study. Cephalalgia 2006;26:871-874